Status:
COMPLETED
Suspected Deficient Activation of Vitamin D in Patients With Secondary Hyperparathyroidism
Lead Sponsor:
University of Maryland, Baltimore
Conditions:
Secondary Hyperparathyroidism
Eligibility:
FEMALE
40-59 years
Phase:
NA
Brief Summary
The purpose of this study is to determine if a reduction in the enzyme 1-hydroxylase, which activates Vitamin D, is the cause of overactivity of the parathyroid glands (called secondary hyperparathyro...
Detailed Description
Vitamin D, an essential nutrient, is produced by the skin after sunlight shines on it. Vitamin D must then be activated by both the liver and the kidneys to perform its function of maintaining strong ...
Eligibility Criteria
Inclusion
- Caucasian female
- Age 40-59 years
- Serum creatinine \< 1.3 and estimated glomerular filtration rate (GRF) \> 60
- Serum calcium in the normal range (for U Md lab 8.6-10 mg/dl)
- Parathyroid hormone in the normal range (for U Md lab 12-54 pg/ml)
- Normal 25-hydroxyvitamin D level (30 ng/ml or higher)
- For women of childbearing age, non-pregnant (based on negative urine pregnancy test on the morning of the teriparatide infusion)
Exclusion
- Non-caucasian
- Age under 40 and over 59 years
- Male
- Serum creatinine over 1.3 or estimated glomerular filtration rate (GFR) \< 60
- Abnormal serum calcium (for U Md lab, below 8.6 or above 10 mg/dl)
- Abnormal parathyroid hormone (for U Md lab, above 65 or below 12 pg/ml)
- For women of childbearing age, non-pregnant (based on urine pregnancy test on the morning of the teriparatide infusion)
- History of bone radiation
- History of Paget disease of bone
- History of bone malignancy or metastases
- History of allergy or sensitivity to Forteo
Key Trial Info
Start Date :
February 1 2007
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
August 1 2008
Estimated Enrollment :
20 Patients enrolled
Trial Details
Trial ID
NCT00754442
Start Date
February 1 2007
End Date
August 1 2008
Last Update
April 1 2022
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
University of Maryland School of Medicine Division of Endocrinology
Baltimore, Maryland, United States, 21201